Wikipedia:Articles for deletion/Hemispherx Biopharma

The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was keep. (non-admin closure) Lourdes 16:35, 25 July 2018 (UTC)[reply]

Hemispherx Biopharma

[Hide this box] New to Articles for deletion (AfD)? Read these primers!

(Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL)

Fails WP:GNG. Google News archive reveals only press releases. Sources cited in article lack depth. See WP:ORGDEPTH. See also Wikipedia:Articles for deletion/Oragen. Daask (talk) 15:55, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Organizations-related deletion discussions. Hhkohh (talk) 16:01, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Companies-related deletion discussions. Hhkohh (talk) 16:01, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Florida-related deletion discussions. Hhkohh (talk) 16:01, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Science-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Technology-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of United States of America-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]

Note: This discussion has been included in the list of Medicine-related deletion discussions. Agricolae (talk) 16:07, 11 July 2018 (UTC)[reply]

Redirect to Rintatolimod - All of the coverage of this company is either WP:ROUTINE, or relates to what appears to be its sole product, the drug Ampligen® (generic name Rintatolimod). The company's role with their drug is already sufficiently documented on that page, and I don't see any coverage that would suggest the company is notable outside of their role with the drug, so I would suggest an analogy to WP:ONEEVENT applies. It is likely anyone who searches for the company's name is interested, one way or another, in the information presented on the drug's page, so a redirect seems the best way to go. Agricolae (talk) 16:19, 11 July 2018 (UTC)[reply]

Keep per the significant coverage in multiple independent reliable sources.

From Wikipedia:Notability (organizations and companies)#Publicly traded corporations (my bolding):

Analyst reports
1. Mahajan, Snehal (2015-04-13). "13 April 2015: Diligence and Valuation Report: Hemisphere Biopharma, Inc". Arrowhead Business and Investment Decisions. Archived from the original on 2018-07-12. Retrieved 2018-07-12.
  This is a 26-page analyst report about the company.
  The report says:
  The report has a business overview section with these subsections:
  1. Product Offerings
  2. Company Premiums
  3. Company Risks
  4. Corporate Strategy
  5. Shareholding Pattern
  6. Listing and Contact Details
  Here is the company overview: The analyst report lists five categories of company risks and provides a paragraph of discussion for each: (1) Unsuccessful Product Development, (2) Uncertainty related to regulatory approval, (3) Cash Flow Uncertainty, (4) Inadequate financial resources/Delay in Commercialization, (5) Reduction in the Incidence of Ebola Cases.
2. Bansal, Abhishek (2015-09-29). "29 September 2015: Diligence and Valuation Report: Hemisphere Biopharma, Inc" (PDF). Arrowhead Business and Investment Decisions. Archived from the original (PDF) on 2018-07-12. Retrieved 2018-07-12.
  This is another analyst report from Arrowhead Business and Investment Decisions.
3. This 3 October 2014 article^archive.is from StreetInsider notes:
4. This article^WebCite from the company notes: This is an analyst report from Griffin Securities about Hemisphere Biopharma.
5. This forum post^WebCite from boursorama.com provides information from a Maxim Group analyst report written by analyst Yale Jen and published in April 2011.
There is sufficient coverage in reliable sources to allow Hemisphere Biopharma to pass Wikipedia:Notability#General notability guideline, which requires "significant coverage in reliable sources that are independent of the subject".
Cunard (talk) 07:53, 12 July 2018 (UTC)[reply]

There is enough coverage about Hemispherx Biopharma's history, products (Alferon N Injection®, Ampligen®, and Alferon®), premiums, and risks to justify a separate article from Rintatolimod (Ampligen), one of its products.
Cunard (talk) 07:53, 12 July 2018 (UTC)[reply]

Keep As per Cunard's analyst reports, meets the criteria for establishing notabilty, passes WP:NCORP. HighKing⁺⁺16:33, 16 July 2018 (UTC)[reply]

Relisted to generate a more thorough discussion and clearer consensus.
Please add new comments below this notice. Thanks, North America¹⁰⁰⁰ 09:45, 18 July 2018 (UTC)[reply]

Keep. Meets WP:CORP with Cunard's analyst reports. — Newslinger talk 12:23, 20 July 2018 (UTC)[reply]

The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.